A Minimalist Binary Vaccine Carrier for Personalized Postoperative Cancer Vaccine Therapy. Issue 10 (31st January 2022)

• Record Type: Journal Article
• Authors: Zhao, Jiayu; Xu, Yudi; Ma, Sheng; Wang, Yibo; Huang, Zichao; Qu, Haoyuan; Yao, Haochen; Zhang, Yu; Wu, Guanglu; Huang, Leaf; Song, Wantong; Tang, Zhaohui; Chen, Xuesi
• Is Part Of: Advanced materials. Volume 34:Issue 10(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-01-31
• Subjects: cancer immunotherapy -- cancer vaccine -- nanovaccine -- polymeric carriers -- postoperative therapy; Materials -- Periodicals; Chemical vapor deposition -- Periodicals; 620.11
• DOI: 10.1002/adma.202109254
• Languages: English
• ISSNs: 0935-9648

Abstract

Abstract: In recent years, significant evolutions have been made in applying nanotechnologies for prophylactic and therapeutic cancer vaccine design. However, the clinical translation of nanovaccines is still limited owing to their complicated compositions and difficulties in the spatiotemporal coordination of antigen‐presenting cell activation and antigen cross‐presentation. Herein, a minimalist binary nanovaccine (BiVax) is designed that integrates innate stimulating activity into the carrier to elicit robust antitumor immunity. The authors started by making a series of azole molecules end‐capped polyethylenimine (PEI‐M), and were surprised to find that over 60% of the PEI‐M polymers have innate stimulating activity via activation of the stimulator of interferon genes pathway. PEI‐4BImi, a PEI‐M obtained from a series of polymers, elicits robust antitumor immune responses when used as a subcutaneously injected nanovaccine by simply mixing with ovalbumin antigens, and this BiVax system performs much better than the traditional ternary vaccine system, as well as, commercialized aluminum‐containing adjuvants. This system also enables the fast preparation of personalized BiVax by compositing PEI‐4BImi with autologous tumor cell membrane protein antigens, and a 60% postoperative cure rate is observed when combined with immune checkpoint inhibitors. Abstract : A novel class of minimalist vaccine carriers based on azole molecules‐modified branched polyethylenimine is reported, which orchestrates the innate stimulating activity and antigen cross‐presentation processes in antigen‐presenting cells and achieves impressive personalized vaccine therapy results with the thus prepared binary vaccine.